Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus

Phase 2positiveLitifilimabPositive

AI Analysis

Summary

Biogen announced positive 52-week Phase 2 data for litifilimab, a first-in-class therapy for cutaneous lupus erythematosus, from the ongoing Phase 2/3 AMETHYST study, demonstrating rapid and durable efficacy.

Clinical Trial Data

Phase

Phase 2/3

Primary Endpoint

Met

Outcome Details

52-week Phase 2 data demonstrates rapid and durable efficacy

Importance:7/10

Sentiment:

0.75

clinical_trialPhase_2_datafirst-in-classlupusdermatology

Related Companies

$BIIB

Read the original article

Published by yahoo_finance on October 2, 2026 3:20 PM

Read Original